Butterfield, Lisa H. http://orcid.org/0000-0002-3439-9844
Najjar, Yana G. http://orcid.org/0000-0002-0138-1664
Article History
Accepted: 8 November 2023
First Online: 6 December 2023
Competing interests
: L.H.B. declares the following unrelated advisory activities: Calidi Scientific and Medical Advisory Board, 6 April 2017–2023; KaliVir, Scientific Advisory Board, 2018–2023; Torque Therapeutics, Scientific Advisory Board, 2018–2020; Khloris, Scientific Advisory Board, 2019–2023; Pyxis, Scientific Advisory Board, 2019–2023; CytomX, Scientific Advisory Board, 2019–2023; DCprime, Scientific Advisory Board meeting, November 2020; RAPT, Scientific Advisory Board, 2020–2023; Takeda, scientific advisor, 2020–2023; EnaraBio scientific adviser, February 2021; Federation Bio, scientific adviser, 2022; and Pfizer, scientific adviser, 2022. Current contact: lisa.butterfield@merck.com. Y.G.N. declares the following unrelated advisory activities: Scientific Advisory Board/consulting: Merck, InterVenn Bio, Novartis, BMS, Pfizer and Immunocore. Non-continuing education honoraria: Immunocore. Travel cost/accommodations: Istari Oncology. Research funding (to institution): Merck, Pfizer, BMS and Replimune.